PRESS RELEASE published on 10/16/2025 at 06:30, 1 year 1 month ago Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America Actor Pharmaceuticals and Megalabs to commercialize Formycon's Eylea biosimilar FYB203 in Australia and Latin America. Partnership agreements include upfront payments and royalties Partnerships Commercialization Biosimilar Formycon Eylea
BRIEF published on 10/02/2025 at 06:35, 1 year 1 month ago Formycon obtient une licence américaine pour le biosimilaire d'Aflibercept Formycon AG Lancement Sur Le Marché Américain Biosimilaire D'Aflibercept Accord Regeneron Résolution Des Litiges En Matière De Brevets
BRIEF published on 10/02/2025 at 06:35, 1 year 1 month ago Formycon Secures U.S. License for Aflibercept Biosimilar Formycon AG U.S. Market Launch Aflibercept Biosimilar Regeneron Agreement Patent Dispute Resolution
PRESS RELEASE published on 10/02/2025 at 06:30, 1 year 1 month ago Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron. Commercial launch expected in Q4/2026 Formycon Regeneron Valorum Biologics Aflibercept Biosimilar Patent Disputes
BRIEF published on 09/17/2025 at 16:00, 1 year 2 months ago Formycon AG : Recherche et prévisions de performance actualisées Prévisions De Revenus Formycon FYB202 Biosimilaires FYB206
BRIEF published on 09/17/2025 at 16:00, 1 year 2 months ago Formycon AG: Updated Research and Performance Forecast Revenue Forecast Biosimilars Formycon FYB202 FYB206
PRESS RELEASE published on 09/17/2025 at 15:55, 1 year 2 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research GmbH updates rating on Formycon AG (ISIN: DE000A1EWVY8) to Buy with a target price of €48. Analyst expects revenue to rebound in H2 and Q4 due to FYB202 and FYB206 developments First Berlin Equity Research BUY Rating Formycon AG Update Target Price
BRIEF published on 09/17/2025 at 06:35, 1 year 2 months ago Horus Pharma rejoint la commercialisation du biosimilaire Eylea® de Formycon Commercialisation Formycon Biosimilaire Baiama Horus Pharma
BRIEF published on 09/17/2025 at 06:35, 1 year 2 months ago Horus Pharma Joins Formycon's Eylea® Biosimilar Commercialization Commercialization Biosimilar Formycon Baiama Horus Pharma
PRESS RELEASE published on 09/17/2025 at 06:30, 1 year 2 months ago Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama® Horus Pharma partners with Formycon for Eylea biosimilar commercialization in Europe under Baiama brand. Agreement includes upfront payments and royalties for Klinge. Aflibercept treats nAMD Agreement Formycon Eylea Biosimilar Horus Pharma Baiama Brand
Published on 11/20/2026 at 02:00, 9 hours 59 minutes ago PPX Mining Announces Completion of Debt Settlement
Published on 11/19/2026 at 23:30, 12 hours 29 minutes ago EQ Inc. Reports Third Quarter 2026 Financial Results
Published on 11/19/2026 at 23:00, 12 hours 59 minutes ago Redwood AI Reports Positive Interim Q-SAFE Findings Supporting Quantum-Assisted Chemical Safety Screening
Published on 11/19/2026 at 22:35, 13 hours 24 minutes ago Pampa Medina Drilling Intersects 102m of 1.0% Cu and 5.1g/t Ag from SPRD-21; 22m of 2.1% Cu and 10g/t Ag from SPRD-18; and 8m of 3.21% Cu and 27.5g/t Ag from SPRD-24
Published on 11/19/2026 at 22:25, 13 hours 34 minutes ago Kidoz Reports Record Nine-Month Revenue of US$9,900,750
Published on 11/20/2026 at 11:29, 30 minutes ago REPLOID implements 15-for-1 stock split and moves from auction to continuous trading
Published on 11/20/2026 at 11:05, 53 minutes ago BIRKENSTOCK EXPANDS IN THE GREEK MARKET WITH THE OPENING OF TWO NEW RETAIL DESTINATIONS IN ATHENS
Published on 11/20/2026 at 10:59, 1 hour ago EQS-Adhoc: Revenue decreases by approximately 28.6% in the first half of the financial year // Positive revenue and earnings outlook for the 2026/2027 financial year remains unchanged
Published on 11/19/2026 at 19:00, 16 hours 59 minutes ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 19:00, 16 hours 59 minutes ago MR.BRICOLAGE : PERSPECTIVES POUR L'EXERCICE 2026
Published on 11/19/2026 at 08:30, 1 day 3 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing
Published on 11/19/2026 at 08:30, 1 day 3 hours ago Souveraineté des données : Cegedim ouvre EB6, un datacenter nouvelle génération pour l'IA et la haute densité